Skip to Content

Publications Search - Abstract View

Title: Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.
Authors: Mai PL,  Malkin D,  Garber JE,  Schiffman JD,  Weitzel JN,  Strong LC,  Wyss O,  Locke L,  Means V,  Achatz MI,  Hainaut P,  Frebourg T,  Evans DG,  Bleiker E,  Patenaude A,  Schneider K,  Wilfond B,  Peters JA,  Hwang PM,  Ford J,  Tabori U,  Ognjanovic S,  Dennis PA,  Wentzensen IM,  Greene MH,  Fraumeni JF Jr,  Savage SA
Journal: Cancer Genet
Date: 2012 Oct
Branches: CGB, OD
PubMed ID: 22939227
PMC ID: PMC3593717
Abstract: Li-Fraumeni syndrome (LFS) is a rare dominantly inherited cancer predisposition syndrome that was first described in 1969. In most families, it is caused by germline mutations in the TP53 gene and is characterized by early onset of multiple specific cancers and very high lifetime cumulative cancer risk. Despite significant progress in understanding the molecular biology of TP53, the optimal clinical management of this syndrome is poorly defined. We convened a workshop on November 2, 2010, at the National Institutes of Health in Bethesda, Maryland, bringing together clinicians and scientists, as well as individuals from families with LFS, to review the state of the science, address clinical management issues, stimulate collaborative research, and engage the LFS family community. This workshop also led to the creation of the Li-Fraumeni Exploration (LiFE) Research Consortium.